A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Trial Profile

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CREDENCE
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Jun 2017 Status changed from recruiting to active, no longer recruiting according to a Janssen media release.
    • 08 May 2017 Planned End Date changed from 20 Jan 2020 to 28 Jun 2019.
    • 06 Apr 2017 Planned primary completion date changed from 11 Feb 2019 to 28 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top